Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-288 in cognitive deficits in schizophrenia
NCT01077700Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2010
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ABT-288 in schizophrenia, sponsored by AbbVie Inc.. Started Mar 2010; status: completed.
02
Drugs
ABT-288
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT01077700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01077700.